RNAZ — Transcode Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $5.49m
- $0.58m
- 10
- 28
- 23
- 10
2019 December 31st | 2020 December 31st | 2021 December 31st | C2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 0.457 | 0.727 | 6.15 | 18.6 | 19.4 |
Operating Profit | -0.457 | -0.727 | -6.15 | -18.6 | -19.4 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.607 | -2.34 | -6.84 | -17.6 | -18.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.607 | -2.34 | -6.84 | -17.6 | -18.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.607 | -2.34 | -6.84 | -17.6 | -18.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.607 | -2.34 | -6.84 | -17.6 | -18.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -57.2 | -221 | -649 | -1,083 | -104 |
Dividends per Share |